Real-world treatment patterns and costs in a US Medicare population with metastatic squamous non-small cell lung cancer

Lung Cancer

Volumn 87, Issue 2, 2015, Pages 176-185

  Davis, Keith L ^a   Goyal, Ravi K ^a   Able, Stephen L ^b   Brown, Jacqueline ^b   Li, Li ^b   Kaye, James A ^a  

^a RTI HEALTH SOLUTIONS   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Costs; Medicare; Resource utilization; Squamous non small cell lung cancer; Survival; Treatment patterns

Indexed keywords

CARBOPLATIN; GEMCITABINE; PACLITAXEL; PEMETREXED;

AGED; ARTICLE; BIOLOGICAL THERAPY; BLACK PERSON; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CAUCASIAN; CLINICAL FEATURE; COST EFFECTIVENESS ANALYSIS; CYTOREDUCTIVE SURGERY; DEMOGRAPHY; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITAL COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; MONOTHERAPY; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; RACE DIFFERENCE; RETROSPECTIVE STUDY; SYSTEMIC THERAPY; UNITED STATES; VERY ELDERLY; CANCER REGISTRY; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL PRACTICE; COMORBIDITY; FOLLOW UP; HEALTH SURVEY; KAPLAN MEIER METHOD; LUNG NEOPLASMS; PATHOLOGY; PATIENT ATTITUDE; TUMOR VOLUME;

AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; COMORBIDITY; FEMALE; FOLLOW-UP STUDIES; HEALTH CARE COSTS; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MEDICARE; NEOPLASM STAGING; PATIENT ACCEPTANCE OF HEALTH CARE; POPULATION SURVEILLANCE; PRACTICE PATTERNS, PHYSICIANS'; SEER PROGRAM; TUMOR BURDEN; UNITED STATES;

EID: 84922518801     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2014.11.002     Document Type: Article

References (49)

1. Siegel R., Ward E., Brawley O., Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA: Cancer J Clin 2011, 61(4):212-236. 10.3322/caac.20121.
2. Howlader N., Ries L.A., Mariotto A.B., Reichman M.E., Ruhl J., Cronin K.A. Improved estimates of cancer-specific survival rates from population-based data. J Natl Cancer Inst 2010, 102(20):1584-1598. 10.1093/jnci/djq366.
3. National Cancer Institute Lung cancer 2011, Available at: http://www.cancer.gov/cancertopics/types/lung [accessed July, 2011].
4. Gold K.A., Wistuba I.I., Kim E.S. New strategies in squamous cell carcinoma of the lung: identification of tumor drivers to personalize therapy. Clin Cancer Res 2012, 18(11):3002-3007. 10.1158/1078-0432.CCR-11-2055.
5. SEER cancer statistics review, 1975-2011 2014, National Cancer Institute, Bethesda, MD, Based on November 2013 SEER data submission, posted to the SEER website, April 2014. Available at: http://seer.cancer.gov/csr/1975_2011/[accessed June 2014].
6. Gkiozos I., Charpidou A., Syrigos K. Developments in the treatment of non-small cell lung cancer. Anticancer Res 2007, 27(4C):2823-2827.
7. Cetin K., Ettinger D.S., Hei Y.-J., O'Malley C.D. Survival by histologic subtype in stage IV nonsmall cell lung cancer based on data from the Surveillance. Epidemiology and End Results Program. Clin Epidemiol 2011, 3:139-148. 10.2147/CLEP.S17191.
8. Scagliotti G.V., Parikh P., von Pawel J., Biesma B., Vansteenkiste J., Manegold C., et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26(21):3543-3551. 10.1200/JCO.2007.15.0375.
9. McKeage M.J., Jameson M.B. Investigators A-SG. Comparative outcomes of squamous and non-squamous non-small cell lung cancer (NSCLC) patients in phase II studies of ASA404 (DMXAA) - retrospective analysis of pooled data. J Thorac Dis 2010, 2(4):199-204. 10.3978/j.issn.2072-1439.2010.02.04.1.
10. Reungwetwattana T., Dy G.K. Targeted therapies in development for non-small cell lung cancer. J Carcinog 2013, 12(December):22.
11. Miller V.A., Hirsh V., Cadranel J., Chen Y.M., Park K., Kim S.W., et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol 2012, 13(5):528-538. 10.1016/S1470-2045(12)70087-6.
12. Barlesi F., Scherpereel A., Gorbunova V., Gervais R., Vikström A., Chouaid C., et al. Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial. Ann Oncol 2014, 25(5):1044-1052. 10.1093/annonc/mdu098.
13. Kim E.S., Neubauer M., Cohn A., Schwartzberg L., Garbo L., Caton J., et al. Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial. Lancet Oncol 2013, 14(13):1326-1336. 10.1016/S1470-2045(13)70473-X.
14. Heigener D.F., Deppermann K.M., Pawel J.V., Fischer J.R., Kortsik C., Bohnet S., et al. Open, randomized, multi-center phase II study comparing efficacy and tolerability of erlotinib vs. carboplatin/vinorelbin in elderly patients (>70 years of age) with untreated non-small cell lung cancer. Lung Cancer 2014, 84(1):62-66. 10.1016/j.lungcan.2014.01.024.
15. Brzezniak C., Carter C.A., Giaccone G. Dacomitinib, a new therapy for the treatment of non-small cell lung cancer. Expert Opin Pharmacother 2013, 14(2):247-253. 10.1517/14656566.2013.758714.
16. Chang S., Long S.R., Kutikova L., Bowman L., Finley D., Crown W.H., et al. Estimating the cost of cancer: results on the basis of claims data analyses for cancer patients diagnosed with seven types of cancer during 1999-2000. J Clin Oncol 2004, 22(17):3524-3530.
17. Cipriano L.E., Romanus D., Earle C.C., Neville B.A., Halpern E.F., Gazelle G.S., et al. Lung cancer treatment costs, including patient responsibility, by disease stage and treatment modality, 1992 to 2003. Value Health 2011, 14(1):41-52. 10.1016/j.jval.2010.10.006.
18. Kutikova L., Bowman L., Chang S., Long S.R., Obasaju C., Crown W.H. The economic burden of lung cancer and the associated costs of treatment failure in the United States. Lung Cancer 2005, 50:143-154.
19. Ramsey S.D., Martins R.G., Blough D.K., Tock L.S., Lubeck D., Reyes C.M. Second-line and third-line chemotherapy for lung cancer: use and cost. Am J Manag Care 2008, 14(5):297-306.
20. Mariotto A.B., Yabroff K.R., Shao Y., Feuer E.J., Brown M.L. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst 2011, 103(2):117-128. 10.1093/jnci/djq495.
21. Davidoff A.J., Tang M., Seal B., Edelman M.J. Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol 2010, 28(13):2191-2197. 10.1200/JCO.2009.25.4052.
22. Duh M.S., Reynolds Weiner J., Lefebvre P., Neary M., Skarin A.T. Costs associated with intravenous chemotherapy administration in patients with small cell lung cancer: a retrospective claims database analysis. Curr Med Res Opin 2008, 24(4):967-974. 10.1185/030079908X280464.
23. Stokes M.E., Muehlenbein C.E., Marciniak M.D., Faries D.E., Motabar S., Gillespie T.W., et al. Neutropenia-related costs in patients treated with first-line chemotherapy for advanced non-small cell lung cancer. J Manag Care Pharm 2009, 15(8):669-682.
24. Ramsey S.D., Howlader N., Etzioni R.D., Donato B. Chemotherapy use, outcomes, and costs for older persons with advanced non-small-cell lung cancer: evidence from Surveillance, Epidemiology and End Results-Medicare. J Clin Oncol 2004, 22(24):4971-4978.
25. Warren J.L., Harlan L.C., Fahey A., Virnig B.A., Freeman J.L., Klabunde C.N., et al. Utility of the SEER-Medicare data to identify chemotherapy use. Med Care 2002, 40(Suppl. 8):IV-55-IV-61.
26. Brown M.L., Riley G.F., Schussler N., Etzioni R. Estimating health care costs related to cancer treatment from SEER-Medicare data. Med Care 2002, 40(Suppl. 8):IV-104-IV-117.
27. Cooper G.S., Virnig B., Klabunde C.N., Schussler N., Freeman J., Warren J.L. Use of SEER-Medicare data for measuring cancer surgery. Med Care 2002, 40(Suppl. 8):IV-43-IV-48.
28. Virnig B.A., Warren J.L., Cooper G.S., Klabunde C.N., Schussler N., Freeman J. Studying radiation therapy using SEER-Medicare linked data. Med Care 2002, 40.(Suppl. 8):IV-49-IV-54.
29. American Joint Committee on Cancer. AJCC cancer staging manual 1997, Lippincott-Raven, Philadelphia. 5th ed. I.D. Fleming, J.S. Cooper, D.E. Henson, R.V.P. Hutter, B.J. Kennedy, G.P. Murphy (Eds.).
30. American Joint Committee on Cancer. AJCC cancer staging manual. Part 1 2002, Springer. 6th ed. F.L. Greene, D.L. Page, I.D. Fleming, A.G. Fritz, C.M. Balch, D.G. Haller (Eds.).
31. Egevad L., Heanue M., Berney D., Fleming K., Ferlay J. Chapter 4: histologic groups. Cancer incidence in five continents. IX 2007, 61-66. IARC Press, Lyon, France. M.P. Curado, B. Edwards, H.R. Shin, H. Storm, J. Ferlay, M. Heanue, P. Boyle (Eds.).
32. Chang E.T., Shema S.J., Wakelee H.A., Clarke C.A., Gomez S.L. Uncovering disparities in survival after non-small-cell lung cancer among Asian/Pacific Islander ethnic populations in California. Cancer Epidemiol Biomarkers Prev 2009, 18(8):2248-2255. 10.1158/1055-9965.EPI-09-0332.
33. Wang S.J., Fuller C.D., Thomas C.R. Ethnic disparities in conditional survival of patients with non-small cell lung cancer. J Thorac Oncol 2007, 2(3):180-190.
34. Govindan R., Page N., Morgensztern D. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006, 24(28):4539-4544.
35. Devesa S.S., Bray F., Vizcaino A.P., Parkin D.M. International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising. Int J Cancer 2005, 117(2):294-299.
36. Hershman D., Hall M.J., Wang X., Jacobson J.S., McBride R., Grann V.R., et al. Timing of adjuvant chemotherapy initiation after surgery for stage III colon cancer. Cancer 2006, 107(11):2581-2588.
37. Sundararajan V., Hershman D., Grann V.R., Jacobson J.S., Neugut A.I. Variations in the use of chemotherapy for elderly patients with advanced ovarian cancer: a population-based study. J Clin Oncol 2002, 20(1):173-178.
38. Charlson M.E., Charlson R.E., Peterson J.C., Marinopoulos S.S., Briggs W.M., Hollenberg J.P. The Charlson Comorbidity Index is adapted to predict costs of chronic disease in primary care patients. J Clin Epidemiol 2008, 61(12):1234-1240. 10.1016/j.jclinepi.2008.01.006.
39. Lang K., Marciniak M.D., Faries D., Stokes M., Buesching D., Earle C., et al. Trends and predictors of first-line chemotherapy use among elderly patients with advanced non-small cell lung cancer in the United States. Lung Cancer 2009, 63(2):264-270. 10.1016/j.lungcan.2008.05.003.
40. Weycker D., Malin J., Kim J., Barron R., Edelsberg J., Kartashov A., et al. Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: a retrospective cohort study. Clin Ther 2009, 31:1069-1081. 10.1016/j.clinthera.2009.05.019.
41. Wedderburn R.W.M. Quasi-likelihood functions, generalized linear models, and the Gauss-Newton method. Biometrika 1974, 61:439-447.
42. Aupérin A., Le Péchoux C., Rolland E., Curran W.J., Furuse K., Fournel P., et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 2010, 28(13):2181-2190. 10.1200/JCO.2009.26.2543.
43. Li B.S., Gong H.Y., Huang W., Yi Y., Yu J.M., Wang Z.T., et al. study of pemetrexed, cisplatin, and concurrent radiotherapy in patients with locally advanced non-small cell lung cancer. Am J Clin Oncol 2012, 35(2):115-119. 10.1097/COC.0b013e318209ab93.
44. Rowell N.P., O'rourke N.P. Concurrent chemoradiotherapy in non-small cell lung cancer. CDS Rev 2004, 4(October):CD002140.
45. National Comprehensive Cancer Network (NCCN) Clinical practice guidelines in oncology: non-small cell lung cancer, version 3 2012, Available at: http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf [accessed April 2013].
46. Karve S., Price G., Davis K.L., Pohl G., Smyth E.N. Comparison of treatment patterns, healthcare utilization, and direct costs in elderly patients with distant-stage small cell lung cancer (SCLC) versus non-small cell lung cancer (NSCLC) using the SEER-Medicare database. Poster presented at the Annual Meeting of the American Society of Clinical Oncology 2012.
47. Spiro S.G., Silvestri G.A. The treatment of advanced non-small cell lung cancer. Curr Opin Pulm Med 2005, 11:287-291.
48. Travis W.D., Travis L.B., Devesa S.S. Lung cancer. Cancer 1995, 75(Suppl. 1):191-202.
49. Yabroff K.R., Lamont E.B., Mariotto A., Warren J.L., Topor M., Meekins A., et al. Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst 2008, 100(9):630-641. 10.1093/jnci/djn103.